Medical/Pharmaceuticals
Mabwell Announces CDE Approval to Initiate Phase III Clinical Trial of 9MW2821 for Urothelial Carcinoma in Combination with PD-1 Inhibitor
SHANGHAI, Aug. 26, 2024 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced that its submission to the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) for "a randomized, controlled, open-label, ...
2024-08-26 22:00
2608
About Circul VS: A Core Continuous Blood Pressure Measurement Technology System Developed in Partnership with Dr. Ehud Baron
SHENZHEN, China, Aug. 26, 2024 /PRNewswire/ -- UTime Limited (NASDAQ: WTO) ("UTime" or the "Company") is excited to announce its collaboration on Circul VS, a core continuous blood pressure measurement technology system developed in partnership with strategic partner, Dr.Ehud Baron. Designed to o...
2024-08-26 21:25
3422
Seegene Develops mpox PCR Test Assays following the WHO Global Health Emergency Declaration
- Develops NovaplexTM MPXV/OPXV Assay and NovaplexTM HSV-1&2/VZV/MPXV Assay - Designed to detect four viruses at once using multiplex PCR technology - Utilize dual internal controls to ensure highly reliable test results - Pledges to supply assays meeting the needs of respective countries SE...
2024-08-26 21:00
3535
World-Renowned Scientist Wah Chiu, Stanford University Professor and Honorary Advisor to Pohang City, visited Korea at the invitation of the Coree Group
- Seminar presentation at the invitation of Dx&Vx and Coree Group SEOUL, South Korea, Aug. 26, 2024 /PRNewswire/ -- Professor Wah Chiu, who visited Korea at the invitation of the Coree Group, led by ChairmanLim Chong Yoon, an inside director of Hanmi Pharmaceutical and the largest shareholder of ...
2024-08-26 21:00
3063
Actinogen announces further positive results on depression in the XanCIDD phase 2a trial
Durable benefits previously reported for the MADRS depression scale are supported by the patient-reported outcome of PGI-S and new MADRS responder analyses that underscore benefit at week 10 with a 50% higher rate of remission of depression SYDNEY, Aug. 26, 2024 /PRNewswire/ -- Actinogen Medic...
2024-08-26 20:30
2392
Peijia Medical Announces 2024 Interim Results
HONG KONG, Aug. 26, 2024 /PRNewswire/ -- Peijia Medical (HKG:9996), a leading Chinese domestic player in the high-growth transcatheter valve therapeutics and neurovascular interventions markets, announced financial results for the six months endedJune 30, 2024 ("the period") on August 23, 2024. ...
2024-08-26 20:30
3371
I-Mab to Participate at the H.C. Wainwright 26th Annual Global Investment Conference
ROCKVILLE, Md., Aug. 26, 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB), a US-based, global, clinical-stage biotech company, exclusively focused on the development of highly differentiated immunotherapies for the treatment of cancer, today announced that management will present at the H.C. Wainwright ...
2024-08-26 19:00
1764
Meihua International Medical Technologies Co., Ltd. to Present at LIVE! with Webull Corporate Connect: Virtual Healthcare Investment Webinar on August 28, 2024
YANGZHOU, China, Aug. 26, 2024 /PRNewswire/ -- Meihua International Medical Technologies Co., Ltd. ("MHUA" or the "Company") (Nasdaq: MHUA), a reputable manufacturer and provider of Class I, II, and III disposable medical devices with operating subsidiaries inChina, today announced that Xin "Stev...
2024-08-26 18:00
2239
CStone Reports 2024 Interim Results and Recent Corporate Updates
* Total revenue of RMB 254.2 million for 2024 H1; achieving first-time profitability with cash reserve atRMB 814 million as of June 30, 2024. * NDA approval of sugemalimab (PD-L1) for Stage IV NSCLC in EU, marking the first successful international approval of aChina domestic anti-PD-L1 mAb. ...
2024-08-23 22:20
8613
Mabwell Announces the CDE Approval of Novel Nectin-4 Targeting ADC to Initiate Phase III Clinical Trial for the Treatment of Cervical Cancer
SHANGHAI, Aug. 23, 2024 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced that its submission to the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) for the "A Randomized, Open-label, Phase II...
2024-08-23 22:00
5674
UTime Limited to Participate in International Medical Fairs and Medical Conferences
SHENZHEN, China, Aug. 23, 2024 /PRNewswire/ -- UTime Limited (NASDAQ: WTO) ("UTime" or the "Company") is pleased to announce its plans to participate in a series of internationally recognized medical fairs and medical conferences. These forthcoming events will provide a valuable opportunity for U...
2024-08-23 21:25
6458
CanariaBio Inc Announces Enrollment Completion of randomized Phase 2 study of Oregovomab in combination with chemotherapy as neo-adjuvant treatment of patients with Advanced Ovarian Cancer
SEOUL, South Korea, Aug. 23, 2024 /PRNewswire/ -- CanariaBio Inc, a leading late-stage biotechnology company, announces the successful completion of enrollment of 88 patients in a randomized Phase 2 study of oregovomab in combination with chemotherapy (paclitaxel and carboplatin)as neo-adjuvant ...
2024-08-23 20:00
5526
GenFleet Announces the First Approval of a KRAS G12C Inhibitor in China for Treatment of Advanced Non-small Cell Lung Cancer Patients Harboring KRAS G12C Mutation
SHANGHAI, Aug. 23, 2024 /PRNewswire/ -- GenFleet Therapeutics, a clinical-stage biotechnology company focusing on cutting-edge therapies in oncology and immunology, announcedChina's National Medical Products Administration has approved Dupert®（fulzerasib, GFH925/IBI351）for the treatment of patien...
2024-08-23 19:30
4765
Corina Intrauterine Drug-Eluting System approved in China as a novel treatment for patients with moderate-to-severe intrauterine adhesions (IUA)
The World's First-in-Class Intrauterine Drug-Eluting System SHANGHAI, Aug. 23, 2024 /PRNewswire/ -- Corina Intrauterine Drug-Eluting System ("Corina"), developed by Yipurun (Shanghai) Biotechnology Co., Ltd. ("YPR"), has received approval inChina (G.X.Z.Z. 20243181461) for use in patients with ...
2024-08-23 18:45
4615
Antengene Announces 2024 Interim Financial Results, Highlights Progress in R&D and Commercialization
SHANGHAI and HONG KONG, Aug. 23, 2024 /PRNewswire/ -- Antengene Corporation (6996.HK) today announced its interim results for the period endingJune 30, 2024 , along with several significant milestones achieved in recent months. Dr. Jay Mei, Antengene's Founder, Chairman, and CEO, stated, "In the...
2024-08-23 12:32
4727
Getinge to acquire Paragonix Technologies, a growth leader in the organ transplantation market
Today, Getinge announces an agreement to acquire 100% of Paragonix Technologies, Inc., a leading organ transport products and services company in the United States for an aggregated purchase price, including upfront and earn out payments, estimated to approximatelyUSD 477 million. GOTHENBURG, Swe...
2024-08-23 05:00
3659
Alzheimer's Association Commends United Kingdom's Approval of Leqembi, But Condemns Decision to Deny NHS Access
CHICAGO, Aug. 23, 2024 /PRNewswire/ -- The Alzheimer's Association welcomes today's decision by theUnited Kingdom's Medicines and Healthcare Products Regulatory Agency (MHRA) to approve Leqembi® (lecanemab) for the treatment of Alzheimer's disease. However, while celebrating this milestone — the ...
2024-08-23 00:31
4084
Ascentage Pharma Announces 2024 Interim Results
ROCKVILLE, Md. and SUZHOU, China, Aug. 22, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing and commercializing both first-in-class and best-in-class therapies for malignancies, today announced its 2024 interim results. During ...
2024-08-22 23:36
6727
Ubie Announces Social Impact Framework, Shows Estimated Patient Life Expectancy Impact of 27,000 Years and Approximately $1BN
* Ubie has taken the lead in implementing a new standard of measurement to evaluate health and economic impact for global digital health startups * The framework uses the pharmaceutical industry's standard of Quality-Adjusted Life Years (QALY) to provide a widely-accepted and transparent impa...
2024-08-22 21:30
2189
Bridge Biotherapeutics and HitGen Initiate Research Collaboration to Advance Novel Cancer Therapeutics Program
* Bridge Biotherapeutics Enters into a joint research agreement with the Chinese drug discovery platform company "HitGen" to accelerate the discovery of new drug candidates for a FIC novel cancer therapeutics program * Aims to strengthen its oncology portfolio with a novel drug candidate for ...
2024-08-22 21:30
2975
Week's Top Stories
Most Reposted
DBS is First Bank in Asia Pacific to Pilot Visa Intelligent Commerce for Everyday Payments
[Picked up by 322 media titles]
2026-02-16 10:00
Marina Bay precinct partners UOB, Marina Bay Sands and Singapore Tourism Board, together with Disney Cruise Line, to illuminate Singapore's skyline with a fireworks sky show
[Picked up by 321 media titles]
2026-02-19 14:30
Little Artists Art Studio, Singapore Shines at Art Capital 2026
[Picked up by 280 media titles]
2026-02-17 19:12
Kung Fu Meets Spring -- Unitree Spring Festival Gala Robots Present "Cyber Real Kung Fu" in the Year of the Horse
[Picked up by 259 media titles]
2026-02-17 14:16SMU MBA Rises in FT Global Rankings, Excelling in ESG, Salary and Value-for-Money
[Picked up by 253 media titles]
2026-02-16 08:00